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We present a case of a single chamber atrial pacemaker implanted for sinus node
dysfunction and treatment of macroreentrant atrial tachycardias with atrial anti-
tachycardia pacing. The patient presented with sustained atrial tachycardia above the
detection rate, however, the device was unable to detect the tachycardia and did not
deliver the programmed therapy. We discuss the nuances of the atrial tachyarrhythmia
detection algorithms, and the programming strategies to maximize detection of atrial
arrhythmias in a single chamber atrial pacemaker.
Copyright © 2015, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Case
A 29-year-old woman presents with a background history of
single ventricle physiology, a modified Fontan procedure, and
recurrent slow macroreentrant atrial tachycardias (AT)
despite catheter ablation. She has severe sinus node
dysfunction but has normal atrioventricular nodal conduc-
tion. She has an implanted Medtronic Revo MRI® SureScan®
pacemaker (Medtronic Inc, Minneapolis, Minnesota). This is a
dual chamber device but only a right atrial lead (Tendril™ STS
2088TC, St. JudeMedical Inc., St. Paul, Minnesota) is connected
to the pacemaker and the ventricular port is plugged. A ven-
tricular lead had not been implanted on account of theial tachycardia/atrial fibri
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mons.org/licenses/by-nctechnical challenges as the systemic venous blood flows from
the right atrial Fontan directly to the pulmonary artery
bypassing the ventricles. Atrial tachycardia/atrial fibrillation
(AT/AF) detection zone is programmed at 111 bpm (using
proprietary custom software to permit programming a slow
detection rate), and following a nominal 60 s detection inter-
val atrial therapy with antitachycardia pacing (ATP) is pro-
grammed. Even though the device is not connected to a
ventricular lead, a dual chambermode (DDDR) is programmed
because ventricular events to generate VeV intervals are
required for this device's AT/AF detection algorithm to be
operative. The pacemaker paces/senses in the atrium but is
unable to sense the 1:1 conducted rhythm in the ventricle, and
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tricular pacing is ineffective because there is no ventricular
lead; therefore, the ventricular pacing output is programmed
at minimum amplitude and pulse width. Programmed pa-
rameters are as follows:Pacing mode DDDR
Lower rate limit (LRL) 75 bpm (800 ms)
Maximum tracking rate (MTR) 110 bpm (545 ms)
Maximum sensor indicated rate (SIR) 110 bpm (545 ms)
Post-ventricular atrial refractory period
(PVARP)
(310 ms)
Paced AV delay (180 ms)
Sensed AV delay (150 ms)
Atrial tachycardia/fibrillation (AT/AF) detection
Rate 111 bpm (541 ms)
Detection interval 60 s
Atrial tachycardia therapy Antitachycardia
pacing (ATP)She is hospitalizedwith signs and symptoms of right heart/
Fontan failure including protein-losing enteropathy and is
noted to be in a persistent AT at 125 bpm (cycle length 480ms).
Interestingly, her device has not detected AT and had not
delivered atrial ATP. Fig. 1, panel A shows a surface ECG
tracing of the presenting AT with 1:1 ventricular conduction,
panel B shows the ongoing rhythm at device interrogation,
panel C showing the underlying AT on suspension of atrial
pacing, and panel D showing termination of AT with delivery
of ATP through the programmer. (i) Why has the device not
detected AT and delivered atrial ATP despite the underlying
AT rate being faster than the detection rate? (ii) What is the
best solution to enable ATP for such AT episodes in the future?Discussion
Different manufacturers have different algorithms for classi-
fying AT/AF for switching to a non-tracking mode or delivery
of atrial tachyarrhythmia therapy like ATP [1e4]. Most current
generationMedtronic devices use the AT/AF Evidence Counter
(Fig. 2, panel A) that keeps a log of VeV intervals with >1 atrial
sensed events including atrial events sensed during atrial
blanking and refractory periods. Every VeV interval with >1
atrial sensed event increases the counter by one, unless the
extra atrial sensed events are classified as far-field R wave
oversensing (usually during the atrial blanking period) using
another algorithm based on the timing pattern of atrial
events. Following an increment due to a VeV interval with >1
atrial sensed events, the subsequent VeV interval further in-
crements the counter by one, even with a single atrial event.
This is done to avoid underdetection of AT/AF due to under-
sensing or slower tachycardias. However, to compensate for
this increment with only one atrial event in a VeV interval, if
the next VeV interval has 1 atrial events the counter de-
creases by one. The AT/AF Evidence Counter is reset to 0 with
delivery of atrial tachyarrhythmia therapy, any time there are
5 consecutive VeV intervals with1 atrial events, or if there is
evidence of sinus rhythm with far field R-wave oversensing.When the pacemaker is programmed in a tracking mode
that tracks atrial events in the ventricle, switch to a non-
tracking mode is required in event of an AT/AF episode to
prevent rapid ventricular pacing rates. This mode switch is
effected once the AT/AF Evidence Counter reaches 3 if, in
addition, the median PP interval (preceding 12 atrial events) is
shorter than the programmed mode-switch interval (Fig. 2,
panel B). If AT/AF is ongoing, the AT/AF Evidence Counter
continues to accrue increments. The rhythm is classified as
AT/AF once the counter is at 32 if the median PP interval is
also shorter than the programmed AT/AF detection interval.
Following further elapse of the detection interval the pro-
gramed therapy (ATP) is delivered if both the counter con-
tinues to be32 and themedian PP interval is shorter than the
detection interval.
It is easy to see why AT detection fails in a single chamber
pacing mode like AAIR. With no programmed ventricular
pacing or sensing, the prerequisite VeV intervals are not
generated. The AT/AF Evidence Counter algorithm requires
these VeV intervals and checks for intervals with 1 atrial
sensed events for diagnosis of AT/AF. This algorithm depends
on more atrial events than ventricular events for diagnosing
AT/AF. If there was a true ventricular lead, an AT with 1:1
atrioventricular conduction will not be classified as AT/AF as
each VeV interval will have exactly 1 atrial event.
Fig. 3 shows the presenting rhythmand overlays the timing
counters for two cycles of repeating events. As mentioned
before, the ventricular port on the pacemaker is plugged and
the ventricular paced events are inconsequential with respect
to actual ventricular activation. The underlying rhythm is
atrial tachycardia with cycle length of 480 ms (125 bpm). The
first atrial sensed event (AS) is tracked by ventricular paced
event (VP) after sensed AV delay (150 ms). The next atrial
sensed event (TS) is tracked by ventricular paced event after a
longer AV interval to comply with maximum tracking rate
(MTR, 545ms/110bpm), thus causingpacemakerWenckebach.
The next atrial sensed event is not tracked as it falls in the
post-ventricular atrial refractory period (PVARP, functional
undersensing). Ventricular pacing at Wenckebach upper rate
causes a switch from atrial-based to ventricular-based timing
cycle (modified atrial-based timing cycle) and the next atrial
pacing (AP) is delivered after elapse of the VA or atrial escape
interval (LRL e paced AV delay ¼ 800e180 ms ¼ 620 ms) [5].
This atrial paced event is followed by a compensatory pause
and the cycle of events continues to loop over. The phenom-
enon of escape atrial pacing following non-tracked atrial beats
in PVARP is not uncommon in dual chamber devices and is a
cause of failure to switch to a non-tracking mode during atrial
tachyarrhythmias, although some algorithms (Filtered Atrial
Rate Interval, St. Jude Medical Inc., St. Paul, Minnesota) [1] do
not exclude the paced atrial events when counting towards
atrial tachyarrhythmia detection.
As seen in Fig. 3, following the non-tracked atrial sensed
event in PVARP, the relatively shorter atrial escape interval
leads to an atrial paced complex before the relatively slow
next AT beat is sensed. This leads to a single atrial sensed
event in this VeV interval. The other VeV intervals are due to
ventricular tracking of atrial sensed events and have 1:1 AV
relationship. As a result, there are no VeV intervals with >1
atrial sensed events. Therefore, the AT/AF Evidence Counter
Fig. 1 e Panel A e Presenting electrocardiogram lead II. Arrows point to every 4th cardiac cycle with subtle evidence of atrial
pacing artifact and change in p-wave morphology in the ST-segment. Note 1:1 conduction of atrial tachycardia to ventricle.
Panel B e The presenting rhythm noted at pacemaker interrogation. On top is the Marker Channel™ and on bottom is the
bipolar atrial electrogram. Note there is no ventricular lead but the pacemaker shows ventricular paced (VP) markers as it is
programmed DDDR. Panel C eMarker Channel™ showing the underlying slow atrial flutter during inhibition of pacing with
the programmer during device interrogation. Panel D e Termination of atrial tachycardia with antitachycardia pacing
delivered through the device programmer. Again shown are the Marker Channel™ on top and the bipolar atrial electrogram
on the bottom. AP, atrial paced; AS, atrial sensed; TP, tachycardia pacing, TS, tachycardia sensed; VP, ventricular paced.
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tion of rhythm as AT/AF (count 32), or delivery of atrial ATP
does not occur.
Knowledge of the AT/AF detection algorithm, as discussed
above and shown in Fig. 2, facilitates understanding and
troubleshooting of the presented problem. An option is to
decrease the lower rate limit in the DDDR mode. This would
increase the atrial sensing window (end of PVARP to atrialescape/VA interval) to preferentially facilitate detection of the
next AT beat following a non-tracked beat in PVARP rather
than deliver atrial pacing. However, the patient needs the
programmed lower rate (75 bpm) for symptomatic benefit.
The best solution is to program to a non-tracking DDIR
mode with shortest allowed AV delay (30 ms) and PVARP
(150ms). The DDIRmode precludes ventricular tracking of the
atrial tachycardia at the maximum tracking rate, thus
Fig. 2 e Panel A e Flow diagram describing the functioning of AT/AF Evidence Counter (Medtronic Inc, Minneapolis,
Minnesota) for detection of atrial tachycardia/fibrillation for mode switch and delivery of atrial tachyarrhythmia therapies.
Atrial sensed events include those in blanking or refractory periods. AT/AF, atrial tachycardia/atrial fibrillation; VeV
interval, ventriculo-ventricular interval. Panel B e A schematic showing the utilization of the AT/AF Evidence Counter
(Medtronic Inc, Minneapolis, Minnesota) for mode-switch, AT/AF detection and delivery of atrial tachyarrhythmia therapies.
AT/AF, atrial tachycardia/atrial fibrillation; PP, interval between 2 consecutive atrial paced/sensed events.
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Fig. 3 e Schematic of pacemaker timing counters overlaid on the corresponding presenting rhythm from Fig. 2 Marker
Channel. Note the pacemakerWenckebach and functional atrial undersensing in PVARP followed by atrial pacing (asterisks)
at elapse of VA or atrial escape interval. AP, atrial paced; AS, atrial sensed; MTR, maximum tracking rate; pAV, paced AV
delay; PVARP, post-ventricular atrial refractory period; sAV, sensed AV delay; TCL, tachycardia cycle length; TS, tachycardia
sense; VA, VA interval; VP, ventricular paced.
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atrial sensed events. The short AV delay and PVARPminimize
the total atrial refractory period and lengthen the atrial
sensing window. This maximizes the opportunity to sense
intrinsic AT beats during the atrial sensing window prior to
the elapse of the ventricular-based timing cycle, and inhibit
atrial pacing (DDIRmode uses ventricular-based timing cycles
for atrial pacing) [5]. It is worthmentioning that in the absence
of a ventricular lead, there is no deleterious effect of having a
short AV interval, PVARP or a non-tracking pacing mode. The
severe sinus node dysfunction in this case circumvents the
issue of inappropriate detection and therapies for AT/AF due
to sinus tachycardia.
In summary, atrial ATP is useful in complex congenital
heart disease patients as they are prone to poorly tolerated
recurrent macroreentrant atrial tachycardias that can be
difficult to ablate [6,7]. Need for atrial ATP in absence of a
ventricular lead is a unique situation when a dual chamber
mode has to be programmed in Medtronic devices to fabricate
VeV intervals. This allows the device to apply the AT/AF Evi-
dence Counter algorithm that detects atrial tachyarrhyth-
mias. Notably, as this algorithm requires presence of VeV
intervals with 1 atrial events, a 1:1 conducted AT will not be
detected by a dual-chamber device with a functional ventric-
ular lead [3,7]. The details of this algorithm and the recogni-
tion that AV delay, PVARP and ventricular tracking are
superfluous in absence of a ventricular lead are critical when
programming the pacing parameters to maximize chances of
detecting atrial tachyarrhythmias. As a corollary, PVARP is
also irrelevant in patients with dual chamber devices with no
VA conduction, and it can be minimized to prevent failure of
tracking of atrial complexes.Financial disclosures
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